for select vaccines
where high perception
of clinical benefit will
drive increased market
penetration.
Why don’t we find
many more vaccine
startups coming up
while the market
share is mostly held by
few players?
Both technology and
capital requirements
are significant barriers
to entry for startups in
the segment. Most of
the current vaccines
are technologically
very complex and even
leading Indian companies
with in-house research
capacity are leaning on
partnerships to gain
technology access. Even
where a startup has a
technology advantage,
the c apital requirements
are hard to surmount
and serve as a significant
deterrent. While initial
proof of concept funding
in the form of non-dilutive
grants is now available to
innovators, subsequent
rounds of funding for
clinical validation are
hard to access given the
continuing paucity of risk
capital for biotech product
development and the co-
funding requirements of
grants.
BIOVOICENEWS.COM
33